HC Wainwright Reaffirms Buy Rating for Sensei Biotherapeutics (NASDAQ:SNSE)

Sensei Biotherapeutics (NASDAQ:SNSE)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They currently have a $4.00 price target on the stock.

Sensei Biotherapeutics Trading Up 0.5 %

Shares of SNSE traded up $0.00 during mid-day trading on Wednesday, reaching $0.52. 8,679,814 shares of the stock traded hands, compared to its average volume of 1,882,727. The company has a market cap of $13.07 million, a price-to-earnings ratio of -0.44 and a beta of 0.17. Sensei Biotherapeutics has a 1 year low of $0.38 and a 1 year high of $1.94. The firm has a fifty day moving average price of $0.50 and a 200 day moving average price of $0.56.

Hedge Funds Weigh In On Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. National Bank of Canada FI grew its stake in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 45,575 shares of the company’s stock after purchasing an additional 35,575 shares during the period. National Bank of Canada FI owned approximately 0.18% of Sensei Biotherapeutics worth $27,000 as of its most recent SEC filing. Institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.